Antoni Wiedlocha funded by the EEA Poland-Norway grants
Antoni Wiedlocha
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Links:
From the National Centre for Research and Development in Poland:
Published in Level 2 journals, first or last author from Oslo University Hospital.
Schroer L, Weirich S, Hammerstad M, Hersleth HP, Grønsberg IA, Hagen L, Slupphaug G, Malecki JM, Jeltsch A, Falnes PØ, Davydova E(2025) Orthologues of the human protein histidine methyltransferase METTL9 display distinct substrate specificities J Biol Chem, 110318(in press) DOI 10.1016/j.jbc.2025.110318, PubMed 40451431
Wensaas A, Blatti C, Terjesen T, Huhnstock S(2025) Long-term outcome of nonoperative treatment of Perthes' disease : only 19% total hip arthroplasty at a mean follow-up of 48 years Bone Joint J, 107-B(6), 657-662 DOI 10.1302/0301-620X.107B6.BJJ-2024-1310.R1, PubMed 40449542
Yao Z, Fang K, Liu G, Bjørås M, Jin VX, Wang J(2025) Integrated analysis of differential intra-chromosomal community interactions: A study of breast cancer Artif Intell Med, 167, 103180(in press) DOI 10.1016/j.artmed.2025.103180, PubMed 40449144